Curevo declares antibody response data from Phase 1 study of CRV-101
Category: #healthcare  By Mateen Dalal  Date: 2020-09-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Curevo declares antibody response data from Phase 1 study of CRV-101

Biopharmaceutical major, Curevo Vaccine, has reportedly announced the release of antibody response data from its completed Phase 1 study that carried out the investigation of CRV-101’s tolerability, safety, and immune system response in numerous formulations.

Sources cite that the vaccine administration has caused a strong antibody response against a key component of the shingles virus at one month following the second vaccination, and at one year. The company has reportedly decided to present the results of their Phase I trial on September 30, 2020 at the World Vaccine Congress Washington’s virtual conference.

According to Myron Levin, the Scientific Advisory Board member at Curevo, CRV-101 is well stood by the vaccine candidate, adding that the immune response calculated by antibodies in the blood propounds that CRV-101 has the capability to be as good as the presently licensed adjuvanted subunit vaccine. Levin has further stated that the candidate will be evaluated in older adults during the second phase of the trial.

George Simon, the Chief Executive Officer of Curevo, has stated that the company’s Phase 1 trial demonstrated extremely well-tolerated results by healthy adults, generating a durable and robust antibody immune response across the evaluated doses. He has further stated that these results are far beyond the company’s expectations and firmly back its rapid advancement to an expanded Phase 2b clinical trial.

The Phase 1 study comprised a total of 89 subjects having solicited reactogenicity adverse events that included no third grade local injection site incidences and only one third grade systemic fever in the highest dose group.

Lisa Shelton, the Associate Director of Clinical Operations at Curevo, has stated that occurrence of grade 2 individual solicited reactogenicity incidents, comprising pain at injection site, were fewer than 6.5 per cent of the total CRV-101 doses. This investigational vaccine has been designed for eliciting immune responses known for playing a key role against the Shingles virus, added Shelton.

 

Source Credits:

https://curevovaccine.com/2020/09/curevo-vaccine-announces-robust-antibody-response-results-of-phase-i-clinical-trial-of-investigational-vaccine-for-shingles-crv-101/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

U.S. FDA issues EUA of casirivimab & imdevimab to treat COVID-19
U.S. FDA issues EUA of casirivimab & imdevimab to treat COVID-19
By Mateen Dalal

The U.S. FDA has recently issued an EUA (emergency use authorization) of casirivimab & imdevimab...

Male Contraceptive Initiative Announces Partnership with Contraline
Male Contraceptive Initiative Announces Partnership with Contraline
By Mateen Dalal

Male Contraceptive Initiative (MCI) announced its partnership with Contraline, Inc., a medical devic...

Accenture makes investment in TripleBlind via Accenture Ventures
Accenture makes investment in TripleBlind via Accenture Ventures
By Mateen Dalal

Accenture, a professional services company, has reportedly made a strategic investment via Accenture...